All In Biotech

Drug Trial Radar · NCT07213583

Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

A Phase 2, Single Arm, Multicenter Study to Evaluate the Pharmacodynamics and Safety of Re-Treatment With ALXN2220 in Patients With Transthyretin Amyloid Cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Aug 28, 2025

Primary completion

Oct 31, 2026

Study completion Oct 31, 2026

Sponsor

Lead sponsor
Neurimmune AGIndustry
Sponsor type
Industry
Collaborators
Alexion Pharmaceuticals, Inc.
First posted
Oct 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.

Conditions

  • Amyloid Transthyretin Cardiomyopathy

Interventions

  • ALXN2220Drug

    Participants will receive ALXN2220 via IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 48 in ECV measured by cMRITime frame: Baseline, Week 48
  2. Change from Baseline to Week 48 in Heart Retention/Whole Body Retention measured by scintigraphyTime frame: Baseline, Week 48

Locations

6 sites in 4 countries. Site status is shown where the registry gives one.

  • Hôpital Henri Mondor

    Créteil, France

  • CHU de Rennes - Hôpital Pontchaillou

    Rennes, France

  • CHU Toulouse - Hôpital Rangueil

    Toulouse, France

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • University Medical Center Groningen

    Groningen, Netherlands

  • Hospital Universitario Puerta de Hierro Majadahonda

    Majadahonda, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.